Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with non-Homologous Recombination Deficient (non-HRD) positive advanced ovarian cancer.

Trial Details

NCT ID
NCT07851025
Phase
PHASE3
Sponsor
AstraZeneca
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Torvutatug samrotecan
  • Bevacizumab
Locations (sample)
  • Tamarac, Florida, United States|26.21286,-80.24977
  • Tampa, Florida, United States|27.94752,-82.45843
  • Baton Rouge, Louisiana, United States|30.44332,-91.18747
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Billings, Montana, United States|45.78329,-108.50069

Key Eligibility Criteria

  • Participants with newly diagnosed FIGO Stage III/IV, histologically confirmed epithelial high-grade ovarian, fallopian tube or primary peritoneal c…
  • Provision of an archival FFPE tumour sample
  • Participants who have completed at least 6 cycles and a maximum of 8 cycles of first-line Platinum-based chemotherapy (PBC) prior to randomisation
  • Participants must have received a minimum of 3 cycles of bevacizumab in combination with the 3 last cycles of PBC, prior to randomisation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →